JNJ · News · 20260909N
MedTech Product And Procedure Trends
JOHNSON & JOHNSON · 2026-09-09 · Importance 39 · Surprise 50
Johnson & Johnson MedTech Chairman Tim Schmid said the company expects growth toward the high end of its previously stated 5%–7% operational market-growth range for 2022–2027. The portfolio is shifting toward cardiovascular products, placing cardiovascular MedTech at the center of the company’s growth strategy. Johnson & Johnson is also investing in differentiated technologies and changing its operating model to support higher-end MedTech growth.